Neurocrine Q3 net product sales rise 28% to $790 million; GAAP EPS $2.04
Neurocrine Biosciences reported third-quarter 2025 results, with total net product sales of $790 million, up 28% from a year earlier, and GAAP diluted earnings per share of $2.04 versus $1.24. The company reaffirmed its full-year 2025 INGREZZA net product sales guidance of $2.5 billion to $2.55 billion and updated its R&D and SG&A expense ranges.
Key points
- Total net product sales were $790 million for the quarter, up 28% year over year and 16% sequentially.
- GAAP net income was $210 million ($2.04 per diluted share), compared with $130 million ($1.24) in the third quarter of 2024.
- CRENESSITY net product sales were $98 million in the quarter, with 540 new patient enrollment start forms.
- Full-year 2025 INGREZZA net product sales guidance of $2.5 billion to $2.55 billion was reaffirmed; GAAP R&D guidance is $1.0 billion to $1.02 billion.
The filing
Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 28, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.